RBD 8076
Alternative Names: RBD-8076Latest Information Update: 30 Aug 2023
At a glance
- Originator Suzhou Ribo Life Science
- Class Amino sugars; Drug conjugates; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hereditary angioedema
Most Recent Events
- 21 Jul 2023 RBD 8076 is available for licensing as of 21 Jul 2023. https://www.ribolia.com/En/bd-and-collaboration
- 21 Jul 2023 Preclinical trials in Hereditary angioedema in China (Parenteral) (Suzhou Ribo Life Science pipeline, July 2023)
- 31 May 2023 Suzhou Ribo Life Science has patent protection for small RNAi technologies in China (Suzhou Ribo Life Science pipeline, July 2023)